Literature DB >> 8407909

The single-stranded DNA aptamer-binding site of human thrombin.

L R Paborsky1, S N McCurdy, L C Griffin, J J Toole, L L Leung.   

Abstract

A new class of thrombin inhibitors based on sequence-specific single-stranded DNA oligonucleotides (thrombin aptamer) has recently been identified. The aptamer-binding site on thrombin was examined by a solid-phase plate binding assay and by chemical modification. Binding assay results demonstrated that the thrombin aptamer bound specifically to alpha-thrombin but not to gamma-thrombin and that hirudin competed with aptamer binding, suggesting that thrombin's anion-binding exosite was important for aptamer-thrombin interactions. To identify lysine residues of thrombin that participated in the binding of the thrombin aptamer, thrombin was modified with fluorescein 5'-isothiocyanate in the presence or absence of the thrombin aptamer, reduced, carboxymethylated, and digested with endoproteinase Arg-C. The digestion products were analyzed by reversed-phase high performance liquid chromatography and the peptide maps compared. Four peptides with significantly decreased modification in the presence of the aptamer were identified and subjected to N-terminal sequence analysis. Results indicated that B chain Lys-21 and Lys-65, both located within the anion-binding exosite, are situated within or in close proximity to the aptamer-binding site of human alpha-thrombin. The thrombin aptamer binds to the anion-binding exosite and inhibits thrombin's function by competing with exosite binding substrates fibrinogen and the platelet thrombin receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407909

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Light-switching excimer probes for rapid protein monitoring in complex biological fluids.

Authors:  Chaoyong James Yang; Steffen Jockusch; Marie Vicens; Nicholas J Turro; Weihong Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

2.  Stability and binding properties of a modified thrombin binding aptamer.

Authors:  Bruno Pagano; Luigi Martino; Antonio Randazzo; Concetta Giancola
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

3.  Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen.

Authors:  Erik W Orava; Aws Abdul-Wahid; Eric H-B Huang; Amirul Islam Mallick; Jean Gariépy
Journal:  Mol Oncol       Date:  2013-04-11       Impact factor: 6.603

4.  High-affinity RNA ligands to human alpha-thrombin.

Authors:  M F Kubik; A W Stephens; D Schneider; R A Marlar; D Tasset
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

5.  The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine.

Authors:  J A Latham; R Johnson; J J Toole
Journal:  Nucleic Acids Res       Date:  1994-07-25       Impact factor: 16.971

Review 6.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

7.  Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope.

Authors:  W Xu; A D Ellington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 8.  In vitro selection methodologies to probe RNA function and structure.

Authors:  R C Conrad; S Baskerville; A D Ellington
Journal:  Mol Divers       Date:  1995-09       Impact factor: 2.943

9.  A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum.

Authors:  J P Shaw; J A Fishback; K C Cundy; W A Lee
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

10.  Protease-resistant peptide ligands from a knottin scaffold library.

Authors:  Jennifer A Getz; Jeffrey J Rice; Patrick S Daugherty
Journal:  ACS Chem Biol       Date:  2011-06-16       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.